588 related articles for article (PubMed ID: 27503237)
1. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials.
Brightling CE; Gaga M; Inoue H; Li J; Maspero J; Wenzel S; Maitra S; Lawrence D; Brockhaus F; Lehmann T; Brindicci C; Knorr B; Bleecker ER
Lancet Respir Med; 2021 Jan; 9(1):43-56. PubMed ID: 32979986
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
4. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.
Barnes N; Pavord I; Chuchalin A; Bell J; Hunter M; Lewis T; Parker D; Payton M; Collins LP; Pettipher R; Steiner J; Perkins CM
Clin Exp Allergy; 2012 Jan; 42(1):38-48. PubMed ID: 21762224
[TBL] [Abstract][Full Text] [Related]
6. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial.
Maspero J; Agache IO; Kamei T; Yoshida M; Boone B; Felser JM; Kawakami F; Knorr B; Lawrence D; Lehmann T; Wang W; Pedinoff AJ
Respir Res; 2021 Dec; 22(1):311. PubMed ID: 34895218
[TBL] [Abstract][Full Text] [Related]
10. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
13. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459.
Pettipher R; Hunter MG; Perkins CM; Collins LP; Lewis T; Baillet M; Steiner J; Bell J; Payton MA
Allergy; 2014 Sep; 69(9):1223-32. PubMed ID: 24866478
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Prostaglandin D2 Receptor 2 Antagonism with Fevipiprant for Patients with Asthma: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yang D; Guo X; Liu T; Li Y; Du Z; Liu C
Curr Allergy Asthma Rep; 2021 Aug; 21(7):39. PubMed ID: 34387775
[TBL] [Abstract][Full Text] [Related]
15. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Russell RJ; Chachi L; FitzGerald JM; Backer V; Olivenstein R; Titlestad IL; Ulrik CS; Harrison T; Singh D; Chaudhuri R; Leaker B; McGarvey L; Siddiqui S; Wang M; Braddock M; Nordenmark LH; Cohen D; Parikh H; Colice G; Brightling CE;
Lancet Respir Med; 2018 Jul; 6(7):499-510. PubMed ID: 29793857
[TBL] [Abstract][Full Text] [Related]
16. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial.
Gibson PG; Yang IA; Upham JW; Reynolds PN; Hodge S; James AL; Jenkins C; Peters MJ; Marks GB; Baraket M; Powell H; Taylor SL; Leong LEX; Rogers GB; Simpson JL
Lancet; 2017 Aug; 390(10095):659-668. PubMed ID: 28687413
[TBL] [Abstract][Full Text] [Related]
17. The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.
Erpenbeck VJ; Popov TA; Miller D; Weinstein SF; Spector S; Magnusson B; Osuntokun W; Goldsmith P; Weiss M; Beier J
Pulm Pharmacol Ther; 2016 Aug; 39():54-63. PubMed ID: 27354118
[TBL] [Abstract][Full Text] [Related]
18. Fevipiprant, an oral prostaglandin DP
Bateman ED; Guerreros AG; Brockhaus F; Holzhauer B; Pethe A; Kay RA; Townley RG
Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28838980
[TBL] [Abstract][Full Text] [Related]
19. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.
Kliewer KL; Murray-Petzold C; Collins MH; Abonia JP; Bolton SM; DiTommaso LA; Martin LJ; Zhang X; Mukkada VA; Putnam PE; Kellner ES; Devonshire AL; Schwartz JT; Kunnathur VA; Rosenberg CE; Lyles JL; Shoda T; Klion AD; Rothenberg ME
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):803-815. PubMed ID: 37336228
[TBL] [Abstract][Full Text] [Related]
20. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
